PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50120C00169Advance the development of crphage as — Locus Biosciences, Inc

Locus Biosciences, Inc holds $56.7M across 2 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Dec 31, 2026 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Locus Biosciences, Inc

Recipient

Dec 31, 2026

PoP end

$62.9M

Obligated

541714

NAICS

AN13

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Locus Biosciences, Inc — $90

Contract facts

NONE

Contract number75A50120C00169

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentLocus Biosciences, Inc

UEICJKVLKZGX6F3

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN13

Place of performanceMORRISVILLE, NC

Related solicitationBAA-18-100-SOL-00003

PoP end (current)Dec 31, 2026

PoP end (w/ options)Jan 1, 2027

Obligated$62.9M

ADVANCE THE DEVELOPMENT OF CRPHAGE AS A CRISPR-ENGINEERED PRECISION ANTIBACTERIAL OF URINARY TRACT INFECTIONS CAUSED BY… is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Locus Biosciences, Inc. Estimated value $73.9M ($62.9M obligated). Current period of performance ends Dec 31, 2026 (potential Jan 1, 2027). Last award drew 1 bidder. Place of performance: MORRISVILLE, NC. Related solicitation BAA-18-100-SOL-00003.

ADVANCE THE DEVELOPMENT OF CRPHAGE AS A CRISPR-ENGINEERED PRECISION ANTIBACTERIAL OF URINARY TRACT INFECTIONS CAUSED BY E. COLI.

Recompete timing

Public

● Expiring in 116 days

Current PoP ends Dec 31, 2026 (116 days remaining). Agencies typically plan 12–18 months ahead — at 3.8 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Locus Biosciences, Inc — $56.7M obligated across 2 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$56.7M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50120C00169?

75A50120C00169 (Advance the development of crphage as) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $73.9M, currently held by Locus Biosciences, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50120C00169?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50120C00169 to Locus Biosciences, Inc.

Who is the incumbent on 75A50120C00169?

Locus Biosciences, Inc is the incumbent with $56.7M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2026.

When does Locus Biosciences, Inc’s 75A50120C00169 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50120C00169 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Sep 16, 2025